Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)

Description

To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H\&N) cancer patients followed in survivorship clinic that received cisplatin-based chemoradiation therapy (CRT).

Conditions

Head and Neck Cancer Survivors, Cancer of the Head and Neck Surviors

Talk to us

Study Overview

On this page

Study Details

Study overview

To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H\&N) cancer patients followed in survivorship clinic that received cisplatin-based chemoradiation therapy (CRT).

Head and Neck Cancer Survivorship Ototoxicity Screening (SOS) Protocol

Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)

Condition
Head and Neck Cancer Survivors
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult (≥ 18 years old)
  • * H\&N cancer patients will be eligible for inclusion if they have previously undergone cisplatin-based CRT or radiotherapy, including proton therapy, intensity-modulated radiation therapy, and adaptive radiotherapy-surgery with curative intent (i.e., definitive, neoadjuvant, or adjuvant) or definitive surgery with neoadjuvant or adjuvant radiation.
  • * Patient has been evaluated by an audiologist within the past 12 months
  • * Use of a hearing aid
  • * Received a cochlear implant
  • * Cannot complete simple forms in English

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Washington University School of Medicine,

David Lee, M.D., PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

2024-12-31